TwitterLinkedin

Contact Us

  • Biopharma Excellence
  • News & Events
    • Industry News Articles
    • Press Releases
    • Webinars
    • Events
    • Blog
    • Podcasts
  • Resource Library
    • Thought Leadership
    • Fact Flyers
    • Case Studies
    • White Papers
    • Webinars
    • Infographics
    • Video & Animation
  • Careers
    • Life at PharmaLex
    • Current Opportunities
  • Training
Top Bar
Search
PharmaLex Logo
MENUMENU
  • PharmaLex Logo
  • PharmaLex Logo
  • About UsAbout Us
    • About Us
    • Management Team
    • Corporate Social Responsibility
    • What Our Clients Say About Us
  • Our Services
    • Discovery / Non-clinical
          • Go to Discovery / Non-clinical section >>

          • Strategy and Consulting

            • Integrated Product Development
            • Market Access
            • Scientific Advice
            • Statistics and Data Sciences
            • Toxicology Services
    • Clinical Development
          • Go to Clinical Development section >>

          • Strategy and Consulting

            • Clinical Program Development
            • Scientific Advice
            • Statistics and Data Sciences
          • Regulatory Affairs

            • Clinical Trial Applications
            • Global Procedure Management
            • Health Authority / Agency Interaction
            • Regulatory Operations
          • Pharmacovigilance

            • Clinical Trial Safety Support
            • Pharmacovigilance Consulting
          • Quality

            • GxP Services
            • Interim / Contract QA
            • Quality Management Systems
            • Tech Transfer / Scale-up
    • Authorization / Approval
          • Go to Authorization / Approval section >>

          • Strategy and Consulting

            • Market Access
          • Regulatory Affairs

            • CMC Services
            • Global Procedure Management
            • Health Authority / Agency Interaction
            • Marketing and Labeling Activities
            • Regulatory Operations
            • Scientific, Regulatory and Technical Writing
            • Statistics and Data Sciences
          • Pharmacovigilance

            • EU QPPV / National QPPV
            • Pharmacovigilance Consulting
          • Quality

            • Commercialization Readiness
            • Commissioning, Qualification, and Validation (CQV)
            • GxP Services
            • Interim / Contract QA
            • PAI Readiness
    • Post-approval / Maintenance
          • Go to Post-approval / Maintenance section >>

          • Strategy and Consulting

            • Market Access
          • Regulatory Affairs

            • CMC Services
            • Global End-to-End Outsourcing
            • Global Procedure Management
            • Health Authority / Agency Interaction
            • Marketing and Labeling Activities
            • Mergers and Acquisitions (M&A) Transfers
            • Regulatory Operations
            • Toxicology Services
          • Pharmacovigilance

            • EU QPPV / National QPPV
            • ICSR (Individual Safety Case Report) Management
            • Literature Monitoring & Screening
            • Pharmacovigilance Quality & Compliance
            • Signal Management
          • Quality

            • Commissioning, Qualification, and Validation (CQV)
            • GxP Services
            • Interim / Contract QA
            • Quality Management Systems
          • Medical Affairs

            • Healthcare Compliance and Medical Approval
    • Program Management
          • Go to Program Management section >>

          • Program Management

            • Global End-to-End Outsourcing
            • Global Procedure Management
            • Integrated Product Development
            • Mergers and Acquisitions (M&A) Transfers
    • Featured Expertise
          • Industry Expertise

            • Biopharmaceuticals
            • MedTech Services
          • Service Expertise

            • ATMP / Cell and Gene Therapy
            • COVID-19 Support
            • GxP Services
            • Market Access
            • Pharmacovigilance Consulting
            • Post-Brexit Regulatory Support
            • Statistics and Data Sciences
            • SMARTPHLEX - technology-enabled services
  • Global ReachGlobal Reach
  • Contact usContact us
  • News & Events
    • Industry News Articles
    • Press Releases
    • Webinars
    • Events
    • Blog
    • Podcasts
  • Resource Library
    • Thought Leadership
    • Fact Flyers
    • Case Studies
    • White Papers
    • Webinars
    • Infographics
    • Video & Animation
  • Careers
    • Life at PharmaLex
    • Career Opportunities
  • Training
Home > Our Services > Market Access

Market Access

The key to unlocking market access, is the ability to look beyond the science, to understand the market dynamics that will shape the future and drive value

To gain market access in pharma and remain competitive, pharmaceutical and medical technology manufacturers must be able to demonstrate clinical and economic evidence to providers, healthcare decision-makers and payers.

In the past, market access for a medicine depended almost exclusively on efficacy and safety. These factors are still critical, but today, clinical differentiation and its effects on healthcare outcomes and resource utilization / optimization require more comprehensive approaches. Today, more than ever, pharmaceutical companies must demonstrate how a new drug improves patient outcomes, reduces the burden of the healthcare system as a whole and is worth its price. To satisfy these criteria, pharmaceutical manufacturers have gradually expanded their strategies ‘beyond the pill’ to build initiatives that take a more holistic view of patient treatment, provide better real-life evidence and therefore a stronger value proposition for decision makers.

For payers and market access stakeholders, the medicine value proposition encompasses the optimal combination of disease need, clinical efficacy and economic impact that achieves market access at an optimal price, in the appropriate setting, by validating and communicating the need for treatment and the value of utilizing the medicine in question in the right setting and to the right patient. To do so, market access activities have expanded significantly beyond pricing and reimbursement, and include other elements such us digital therapeutics, better integration of health/patient reported outcomes in healthcare decisions, or even value-based strategies amongst others.

In the increasing yet infant space of digital therapeutics, the challenges start early on when trying to reconcile the technology, the therapeutic objectives and the regulatory requirements for commercialization. The implications of MDR, go far beyond regulatory compliance, as it can impact the go to market strategies and associated revenue streams. Additionally, can hamper the potential data monetization strategies when appropriate, as well as other growth aspiration, and we look at it from that point of view, and can advise you on best alternatives according to your company and solution’s reality.

We can help you navigate the increasingly complicated legislative and market environment. Each stakeholder has their own particular interest in a product, and we can help you communicate the value of your product to stakeholders.

Let’s tailor a service plan that works for you

PharmaLex. Confidence beyond compliance.

Schedule an introductory call today!

Unlocking market access

Common challenges
  • Heterogenous approaches and policies and processes across countries
  • Complex regulatory and reimbursement pathways, varied evidence requirements and long procedural timelines pose risk to successful access and launch
  • Lack of consistently maintained, integrated information resources
  • Expensive and time-consuming country market research requiring multiple resources to procure data that may not be current
  • Increasing use of MEAs (managed entry agreements) significantly impacting pricing and reimbursement negotiations
  • OVERALL: there is growing disconnect between key stakeholders- Industry, Payers, Physicians and Patients – leading to lack of alignment on what constitutes value and, consequently, driving price pressures

The right strategy is the difference between success and failure. It is imperative to ensure that your clinical development plans are aligned with your commercial goals and the market landscape realities. Failure to do this costs time and money.

Beyond the science

Staying one step ahead
  • We utilize our experience of over 25 years building up knowledge and recognition in the pharma, biotech and medical devices industries
  • We help clients navigate the increasingly complicated regulatory environment to enable them to develop a stronger value offering and concomitant value story for payers
  • Our global network of local experts ensures we understand the local nuances which is vital for a successful outcome
  • Every solution is tailored to the client’s specific needs to provide patients with value-based healthcare and improve clinical outcomes
  • We look beyond the science to increase success in market access and ultimately benefit patients

Market access for a drug once depended almost exclusively on efficacy and safety. Whilst these factors are still critical, clinical differentiation and its effects on cost effectiveness is gaining importance.

Understanding the market dynamics

The importance of understanding your market
  • What is the level of competition
  • Perception of clinical landscape and the influence of therapeutic area (TA) and disease type on profitability
  • Understanding the impact of unmet needs
  • The degree of personalization
  • Use of HTAs to examine the consequences of using a healthcare technology by considering the medical, social, economic and ethical issues
  • Identifying payer priorities, uncertainties and preferences
  • How to demonstrate value

The requirements of the market constantly change. Rising drug spending and increased desire for expenditure controls are a consistent theme and with governments under pressure to fund high-cost, innovative therapies, which often launch with limited clinical trial evidence, payers are looking towards new and enhanced reimbursement processes which align drug funding with patient value.  Today, more than ever, pharmaceutical companies must demonstrate how a new drug improves patient outcomes, reduces the burden of the healthcare system as a whole and is worth its price.

Shaping the future

The rise of digital health and value-based healthcare
  • Digital health is a growing market but there is limited understanding of market access / go-to-market strategies
  • New legal procedures for the assessment of medical devices of higher risk classes (2b and 3) impose new challenges for market access and reimbursement
  • The market access requirements for products which fall into this category are very different from the usual market access regulations, including the distribution network
  • At the same time, the demand for value-based healthcare is increasing and it is important to not only embrace new technologies but ensure it can be demonstrated that healthcare is more sustainable, affordable and patient-orientated

The future of market access is changing. New products and technologies are being introduced which are influencing the future market. We deliver expert knowledge on clinical data, define the value generation of medications or devices and have full understanding of global regulatory requirements as well as market access regulations – all product types are being worked on including borderline products and new digital health services.

Related News

PharmaLex broadens market access and HEOR reach
PharmaLex broadens market access and HEOR reach
4th June 2021
Alternative Pathways for Medical Device Market Authorisation
Alternative Pathways for Medical Device Market Authorisation
29th April 2021
PharmaLex expands France BENELUX region
PharmaLex expands France BENELUX region
16th March 2021

Related Resources

Fact Flyers

  • Real World Evidence

Webinars

  • Healthcare system resilience during and after the pandemic
  • Early-Phase Modelling – Costs and Effectiveness in Pharma

Infographics

  • Early Phase Modeling

Related Services

  • Healthcare Compliance and Medical Approval

What our clients say

Worked with us and our contractors to help us achieve our tight targets, operate with our systems and procedures and are considered invaluable part of our team

US based large development group
VP Regulatory / Quality

In these unprecedented times, PharmaLex continues to support all clients by meeting virtually and providing experienced, remote-based consultants.

PharmaLex Team Thomas
Thomas Dobmeyer, CEO PharmaLex
CEO PharmaLex
Biopharma Excellence Website Image

PharmaLex Brings You Biopharma Excellence

Biopharma Excellence is a fusion of three scientific powerhouses, PharmaLex, ERA Consulting and Biopharma Excellence – all under the PharmaLex brand. This global team of scientific, regulatory and commercial professionals provide strategic product development and proactive regulatory services to developers of biopharmaceuticals, cell and gene therapies, monoclonal antibodies (MABs), vaccines and biosimilars.

Visit Website
USEFUL LINKS
  • Home
  • Contact us
  • Imprint
  • Data Protection
  • Terms and Conditions
RECENT TWEETS
pharmalexglobal PharmaLex @pharmalexglobal ·
6h

Join our webinar to learn more about 👉 Integrated product development for new osteoarthritis treatments on September 20, 4-5 PM CET

Register now: https://go.pharmalex.com/pharmalex-webinar-integrated-product-development-osetoarthritis-treatments?utm_source=SocialMedia&utm_medium=Webinar&utm_campaign=IPD

COVID-19 NEWSLETTER SIGN UP

SIGN UP NOW

WHAT OUR CLIENTS SAY
  • Hard working and there when you need them

    Europe based large biotech
    Regulatory Manager
PharmaLex
©2022 PharmaLex GmbH. All rights reserved.

ISO9001:2015 LogoEnergie Audit LogoSGS Logo

Suspicious Emails

We are aware of a number of suspicious emails about recruitment in circulation purporting to be from PharmaLex. Emails sent by PharmaLex will originate from @pharmalex.com. Should you receive an email and are unsure as to its validity, please report it to contact@pharmalex.com.

Many thanks for your understanding.

The PharmaLex Team

    Please DO NOT send us event/conference information.
    We will not respond and these will be deleted immediately.





    Select your state:

    .
    You can unsubscribe at any time at data.protection@pharmalex.com

    If you do not wish to receive any communication from us, you can unsubscribe at any time at. Click here to view our Privacy Policy.

      Please DO NOT send us event/conference information.
      We will not respond and these will be deleted immediately.





      Select your state:

      Privacy Policy

      .
      If you do not wish to receive any communication from us, you may unsubscribe at any time.

      #AskTheExpert #TogetherBEYONDCOVID19





        Select your state:

        .
        You can unsubscribe at any time at data.protection@pharmalex.com

        If you do not wish to receive any communication from us, you can unsubscribe at any time at. Click here to view our Privacy Policy.

        #TogetherBEYONDCOVID19

        We closely monitor developments and updates surrounding the current outbreak of Coronavirus Disease 2019 (COVID-19) from official sources including the World Health Organisation and are following the guidance and direction of the governments and the local authorities. We are taking this situation very seriously and our number one priority is the safety and business continuity for our customers and colleagues. As ever, we will do everything we can to ensure that services are delivered within the required time and the trusted quality PharmaLex is known for